Certified by Founder
Lodge
MSInsight
start up
France
- Paris
- 11/03/2025
- Seed
- $1,735,762
MSInsight, a French health-tech company, empowers the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status.
MSI has been shown to be an indicator of treatment response, especially for immune checkpoint inhibitors, and as an important pan-cancer biomarker.
We aim to propose bioinformatic tools for delivering insights on microsatellite mutational variations using Next-Generation Sequencing (NGS) data. Our flagship product, MSIcare, will be available as a robust diagnostic, prognostic, and theranostic assistant for guiding clinical decision-making.
- Industry Medical Equipment Manufacturing
- Website https://www.msinsight.tech/
- LinkedIn https://www.linkedin.com/company/msinsight/
Findd.AI | $21,000,000 | (May 22, 2026)
CVRD Health | $5,000,000 | (May 22, 2026)
checker | $8,000,000 | (May 22, 2026)
Oorja Bio | $30,000,000 | (May 22, 2026)
Neurosoft Bioelectronics | $7,500,000 | (May 22, 2026)
Imperagen | $5,000,000 | (May 22, 2026)
Hark(1) | $700,000,000 | (May 22, 2026)
Dandelion Health | $14,000,000 | (May 22, 2026)
Century Health | $5,000,000 | (May 22, 2026)
shatterdome energy | $3,500,000 | (May 22, 2026)
LawX | $8,709,375 | (May 22, 2026)
Overwatch AI | $1,500,000 | (May 22, 2026)
Tribal(1) | $10,000,000 | (May 22, 2026)